Diabetes Care Devices - Australia

In Australia, revenue in the Diabetes Care Devices market market is projected to reach US$446.50m in 2024.
This revenue is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 12.71%, leading to a market volume of US$812.00m by 2029.
In a global context, the majority of revenue will be generated the United States, which is anticipated to reach US$11.71bn in 2024.
In Australia, the Diabetes Care Devices market is increasingly embracing digital health innovations, enhancing patient adherence and remote monitoring capabilities.

Definition:
The Diabetes Care Devices market, a medical technology market, includes medical devices used in the management and treatment of diabetes. These devices range from blood glucose meters and continuous glucose monitoring systems to insulin pumps, insulin pens, and other related accessories. It is important to note that the market does not include pharmaceutical products used in the treatment of diabetes, such as insulin and oral hypoglycemic agents.

Additional information:
Market values represent revenues paid to primary vendors at manufacturer price level either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), enterprises (B2B), and governments (B2G). Revenues are allocated to the country where the money is spent.

Key players in the market include Medtronic, Abbott Laboratories, and Roche Diagnostics. Further information on the key players can be found in the Market Shares boxes.

Blood glucose monitoring devices
Insulin delivery devices

Diabetes drugs
Diabetes supplements

The Diabetes Care Devices Market in Australia is witnessing considerable growth, fueled by factors such as the rising prevalence of diabetes, advancements in technology, and heightened awareness of diabetes management among patients and healthcare providers.

Customer preferences: Consumers in Australia are increasingly prioritizing personalized diabetes management solutions, leading to a growing demand for smart glucose monitoring devices and insulin delivery systems. There is a notable shift towards telehealth platforms that facilitate real-time communication between patients and healthcare professionals, reflecting a desire for convenience and timely support. Additionally, younger demographics are embracing mobile health applications, integrating diabetes management into their daily routines, and fostering a culture of proactive health engagement.

Trends in the market: In Australia, the Diabetes Care Devices Market is experiencing a significant shift towards advanced glucose monitoring technologies and automated insulin delivery systems. Patients increasingly prefer devices that provide real-time data and connectivity, enhancing their ability to manage diabetes effectively. The rise of telehealth services is also notable, as individuals seek remote consultations and ongoing support from healthcare professionals. Furthermore, the integration of mobile health applications is fostering a proactive approach to diabetes management, especially among younger users, which may drive innovation and competition among industry stakeholders to develop user-friendly, interconnected solutions.

Local special circumstances: In Australia, the Diabetes Care Devices Market is influenced by unique geographical and cultural factors. The vast and diverse landscape poses challenges in accessing healthcare for remote communities, prompting a greater reliance on telehealth services and mobile health applications. Additionally, a culturally diverse population drives demand for personalized diabetes management solutions that cater to varying health literacy levels. Regulatory support for innovative medical technologies further accelerates market growth, encouraging local companies to develop user-friendly, interconnected devices that enhance patient engagement and self-management.

Underlying macroeconomic factors: The Diabetes Care Devices Market in Australia is notably shaped by macroeconomic factors such as national economic stability, healthcare expenditure, and demographic trends. A robust national economy supports increased investment in healthcare innovation and infrastructure, facilitating the development and adoption of advanced diabetes management devices. Moreover, rising healthcare costs and a growing prevalence of diabetes necessitate effective solutions, driving demand for cost-effective technologies. Fiscal policies that prioritize health spending and incentivize research and development further enhance market dynamics, while the aging population and urbanization trends create additional pressure on diabetes care, prompting a shift towards more accessible and user-friendly devices.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Medical technology plays a role in the lives of everyone. It includes most of all, medical devices which simplify the prevention, diagnosis, and treatment of diseases and illnesses. The most well-known medical technology products are, among others, pacemakers, imaging instruments, dialysis machines, and implants. The global medical technology industry was worth over 567 billion U.S. dollars annually. Established centers of this industry include North America and Western Europe. The United States is home to the world’s largest medical technology companies. As of 2022, Abbott Laboratories had the largest global revenue at over 31.2 billion U.S. dollars. The main focus of devices manufactured by the Chicago-based company are diagnostics, cardiovascular, and diabetes care. Two other medtech companies that round off the top three largest companies –Medtronic and Johnson & Johnson – are both based in the United States. Although, industry trends show that Asia, and in particular China, is about to play a more prominent role in the years to come.